https://www.selleckchem.com/pr....oducts/c-176-sting-i
No differences in the overall survival has been observed between sequences starting with docetaxel versus AA/ENZ. Between AA-to-ENZ and ENZ-to-AA sequence, the AA-to-ENZ sequence appeared to be more favorable than the ENZ-to-AA regarding progression-free survival but not overall survival. Carbazitaxel seemed to retain its activity regardless of the treatment sequence. Of note, ENZ and apalutamide have been approved in non-metastatic CRPC.Objective To investigate the coronavirus disease 2019 (COVID-19) status of patients wi
Like
Comment
Share
